AIM
- AIM ImmunoTech Inc.
()
Overview
Company Summary
AIM ImmunoTech Inc. (AIM) is a biopharmaceutical company specializing in the development and commercialization of immune-enhancing therapies for infectious diseases, including viral and bacterial infections, as well as certain types of cancers. AIM primarily focuses on leveraging the power of the immune system to fight various diseases.
One of AIM's core areas of research and development is the utilization of a molecule called Ampligen�. Ampligen� is a patented, double-stranded RNA drug that is designed to enhance the body's immune response to infections and diseases. The key principle behind Ampligen� is to boost the immune system, enabling it to better detect and eliminate pathogens and abnormal cells.
AIM ImmunoTech primarily targets infectious diseases caused by RNA viruses, such as influenza, Ebola, SARS-CoV-2 (the virus causing COVID-19), and HIV. They aim to develop novel therapies that can improve patient outcomes and potentially reduce the severity and duration of these types of infections.
Beyond viral infections, AIM is also exploring the potential of Ampligen� in treating cancers. The company is investigating the drug's ability to stimulate the immune system's response against diverse forms of cancer, which could potentially enhance the effectiveness of existing cancer treatments or pave the way for new immunotherapies.
In addition to its drug development efforts, AIM ImmunoTech engages in clinical trials to demonstrate the safety and efficacy of its pipeline products. By gathering scientific evidence, AIM aims to obtain regulatory approvals from relevant authorities, which would allow them to bring their therapies to market and potentially make a positive impact on patient care.
Overall, AIM ImmunoTech Inc. is dedicated to advancing the field of immune system modulation through their research, development, and potential commercialization of immune-enhancing therapies for infectious diseases and cancers.